ISO 10993-1 Update: How Manufacturers Should Revise Their Strategy

## ISO 10993-1 Update: A Strategic Guide for Medical Device Manufacturers The anticipated update to ISO 10993-1, the foundational standard for the biological evaluation of medical devices, represents a significant evolution in regulatory expectations. This change solidifies the industry's move away from a "checklist" approach to biocompatibility testing and toward a comprehensive, risk-based framework. For manufacturers, this shift necessitates a proactive and strategic revision of how biocompatibility is assessed and documented for both new and existing devices. Successfully navigating this update requires more than just acknowledging the new version of the standard. It demands a holistic approach centered on a robust Biological Evaluation Plan (BEP), deep material and chemical characterization, and a scientifically sound toxicological risk assessment. This article provides a practical framework for manufacturers to perform gap analyses, adapt their strategies for new submissions, manage legacy products, and effectively engage with regulatory bodies like the FDA. ### Key Points * **Risk-Based Approach is Paramount:** The update reinforces that biocompatibility is not a series of checkboxes but an ongoing risk management process. A comprehensive Biological Evaluation Plan (BEP) is the central document that guides this process from start to finish. * **Chemical Characterization as the Foundation:** Understanding a device's material composition and manufacturing process is no longer optional. Rigorous chemical characterization (e.g., extractables and leachables testing) is now the primary method for identifying potential biological risks. * **Toxicological Risk Assessment (TRA) is Crucial:** A TRA translates chemical characterization data into an assessment of patient safety. A well-executed TRA is the key to justifying testing plans and, where appropriate, omitting certain historical in-vivo animal tests. * **Gap Analysis for Legacy Devices is Essential:** Manufacturers must systematically review their existing device portfolios to identify and address any gaps between their original biocompatibility data and the requirements of the updated standard. * **Legacy Devices are Not Grandfathered:** Changes to a marketed device's materials, suppliers, or manufacturing processes (including sterilization) can trigger the need for a re-evaluation against the latest version of the standard. * **Proactive FDA Engagement De-Risks Submissions:** For complex situations, novel materials, or justifications to omit testing, the Q-Submission program is an invaluable tool for gaining FDA feedback on a proposed strategy before committing to a final submission package. ### The Shift from Checklist Testing to a Holistic Risk Management Process Historically, demonstrating biocompatibility often involved conducting a prescribed battery of tests from the matrix in ISO 10993-1 based on device category and contact duration. While straightforward, this "checklist" approach could lead to unnecessary animal testing and sometimes failed to identify material- or process-specific risks. The modern approach, emphasized in recent and upcoming versions of ISO 10993-1, treats biological evaluation as an integrated part of the device's overall risk management process, as required under standards like ISO 14971. The core of this process is the **Biological Evaluation Plan (BEP)**. The BEP is a living document that outlines the entire strategy for assessing a device's safety. It begins not with a list of tests, but with a deep dive into the device itself: * All materials of construction (including colorants, plasticizers, and processing aids). * All manufacturing processes that contact the device (e.g., cleaning, polishing, sterilization, packaging). * The intended clinical use, including the nature and duration of patient contact. * Information from suppliers and any available literature on the materials. Based on this information, the BEP identifies potential biological risks and proposes a plan to address them. This plan prioritizes chemical characterization and toxicological risk assessment first, using in-vivo biological testing only to answer specific questions that cannot be addressed by other means. ### Framework for a Gap Analysis on a Legacy Device Portfolio For manufacturers with devices already on the market, the updated standard requires a systematic review to ensure continued compliance. A simple declaration of conformity to the old standard is no longer sufficient, especially when future changes are made or if the device is submitted to a new regulatory body. A structured gap analysis can be performed using the following framework: 1. **Inventory and Categorize Devices:** Group existing products into logical families based on shared materials, manufacturing processes, patient contact type, and the standard version under which they were originally evaluated. This prevents redundant work. For example, all catheters made from the same PVC compound and sterilized with the same EtO cycle could be one family. 2. **Review the Existing Biological Evaluation File:** For each device family, compile all historical biocompatibility data. This includes original test reports, material specifications, and any documented justifications. 3. **Identify Gaps Against the Updated Standard:** Compare the existing file to the new requirements. Key gaps often include: * **Lack of a Formal BEP:** Many older files consist only of test reports without the overarching strategic plan. * **Insufficient Chemical Characterization:** Older submissions may lack rigorous extractables and leachables (E&L) data that is now expected, especially for long-term implants. * **Absence of a Toxicological Risk Assessment (TRA):** If E&L data exists, was it formally assessed for patient risk by a qualified toxicologist? * **Outdated Testing Methods:** Were older tests performed to standards that have since been revised? 4. **Risk Assessment and Prioritization:** Not all gaps carry the same weight. Prioritize remediation efforts based on device risk. A long-term implant made from a novel material with no BEP presents a much higher compliance risk than a surface-contacting, limited-duration device with a minor documentation gap. 5. **Develop a Remediation Plan:** Based on the prioritized gaps, create an action plan. This may range from simple documentation updates (e.g., authoring a BEP that summarizes existing data) to commissioning new chemical characterization studies and a TRA to fill critical data gaps. ### Adapting Strategy for New and Legacy Devices The updated standard affects both new submissions and marketed products, but the strategic approach differs. #### Scenario 1: A Minor Manufacturing Change to a Legacy Device * **Situation:** A company manufactures a line of PEEK spinal implants that were cleared years ago. They decide to switch to a new, validated supplier for their cleaning agent used prior to packaging. * **What Triggers a Re-evaluation:** This change in a manufacturing process directly impacts the device's surface chemistry and introduces a potential source of new chemical residues. According to FDA guidance and ISO standards, this triggers a re-evaluation of the impacted biocompatibility endpoints. * **Strategic Approach:** Instead of repeating the entire original biocompatibility test panel, the manufacturer should adopt a risk-based approach: 1. **Update the BEP:** Document the change and conduct a risk assessment focused specifically on the potential impact of the new cleaning agent. 2. **Perform Targeted Chemical Characterization:** Conduct an E&L study on finished devices processed with the new agent, focusing on identifying and quantifying any new residues. 3. **Conduct a TRA:** A qualified toxicologist assesses the health risk of any identified residues. If the levels are well below established safety limits, the TRA can conclude that the change does not introduce new biological risks. 4. **Document the Conclusion:** The updated BEP, chemical analysis, and TRA are compiled into a Biological Evaluation Report (BER) that justifies why further biological testing is not necessary. This documentation is placed in the device's technical file and quality management system, as required by regulations like 21 CFR Part 820. #### Scenario 2: A New Device with a Novel Surface Coating * **Situation:** A company is developing a new coronary stent with a novel surface coating designed to improve healing. * **What Regulators Will Scrutinize:** As a permanent implant with novel material contact, this device will face the highest level of scrutiny. Regulators will focus on the long-term stability of the coating, its degradation products, and the systemic and local tissue response. * **Strategic Approach:** 1. **Develop a Comprehensive BEP from Day One:** This plan will serve as the roadmap. It will identify the need for extensive chemical characterization, degradation studies, and a thorough TRA. 2. **Conduct Exhaustive Chemical Characterization:** This includes not only standard E&L testing but also simulated use and degradation studies (per ISO 10993-13, -14, and -15) to identify what the coating breaks down into over its intended life. 3. **Perform a Multi-Stage TRA:** The TRA will need to assess the risk of chemicals leaching from the initial device as well as the risk of all identified degradation products over time. 4. **Justify a Focused Testing Plan:** For such a high-risk, novel device, a TRA alone is unlikely to eliminate all in-vivo testing. However, it can be used to argue against certain tests (e.g., acute systemic toxicity) while justifying the need for others (e.g., a long-term implantation study to assess local tissue response), creating a more targeted and scientifically sound plan. ### Strategic Considerations and the Role of Q-Submission When a manufacturer's biocompatibility strategy relies heavily on a complex TRA to justify omitting major biological tests, especially for higher-risk devices, it is prudent to seek FDA feedback. The Q-Submission program is the ideal mechanism for this. A Q-Submission for biocompatibility should not be a high-level query. To be effective, it must present a well-developed scientific argument. Best practices include: * **Submit a Mature BEP:** Provide the FDA with a comprehensive draft of the Biological Evaluation Plan. * **Provide All Supporting Data:** Include the full chemical characterization report and the complete toxicological risk assessment. * **Ask Specific, Pointed Questions:** Do not ask, "Is our biocompatibility plan acceptable?" Instead, ask targeted questions like: * "Based on the attached chemical characterization data (Attachment A) and toxicological risk assessment (Attachment B), which concludes that all identified leachables are below their respective safety thresholds, does the Agency agree that a chronic systemic toxicity study (per ISO 10993-11) is not required for this device?" * "We propose to leverage the biocompatibility data from Device X for our new Device Y. The attached justification (Attachment C) details the similarities in materials and processing. Does the Agency find this justification approach to be scientifically sound?" This proactive engagement can save significant time and resources by aligning with the FDA on the proposed strategy *before* a final marketing submission is filed. ### Finding and Comparing Biocompatibility Testing Services Providers Choosing the right laboratory partner is critical for successfully navigating the updated ISO 10993-1 landscape. A provider should be more than just a testing facility; they should be a strategic partner. When evaluating providers, consider the following: * **Expertise Beyond Animal Testing:** Look for labs with strong analytical chemistry and toxicology departments. They should have extensive experience performing E&L studies (ISO 10993-18) and writing TRAs (ISO 10993-17). * **Regulatory Experience:** The provider should have a deep understanding of current FDA guidance and expectations regarding the use of risk-based approaches. * **GLP Compliance:** Ensure any nonclinical laboratory studies are conducted in compliance with Good Laboratory Practice regulations, such as 21 CFR Part 58. * **Strategic Consultation:** The best partners will help develop the BEP, design efficient testing strategies, and interpret complex data, not just deliver a test report. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ### Key FDA References When developing a biocompatibility strategy for the US market, sponsors should always consult the latest versions of relevant FDA guidance documents and regulations. While not an exhaustive list, key references include: * FDA Guidance: "Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process'" * FDA's Q-Submission Program Guidance * 21 CFR Part 820 – Quality System Regulation * 21 CFR Part 58 – Good Laboratory Practice for Nonclinical Laboratory Studies --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*